History of Alembic Pharmaceuticals Limited 

_x000D_ Incorporated in 2010, Alembic Pharmaceuticals Limited is involved in the manufacturing and trading Active Pharmaceutical Intermediates (API) and finished dosage formulations._x000D_ _x000D_ The company started in 1904, with the manufacture of alcohol and tinctures in Vadodara. Later, in 1940, they started the production of vitamins, cough syrups, sulphur drugs and tonics. In 1961, the company inaugurated the Penicillin plant. In 1967, the company started bulk manufacturing of Vitamin B12, and later, in 1971, they manufactured Erythromycin, the first in India. This was followed by the launch of Althrocin. By 1997, Althrocin had become a top-selling brand in India._x000D_ _x000D_ In 2001, the company started the production of Cephalosporin C. In 2011, the company was demerged from the Alembic Group and Alembic Pharmaceuticals Limited was listed as a separate company. In 2012, Alembic Pharmaceuticals Limited entered the dermatology division with 8 products. The next year, the company had its first Non-Disclosure Agreement (NDA) with a partner and started filing in Brazil, EU and Australia. In 2015, the company launched Aripiprazole, established front-end operations in the United States, and shifted to in-house marketing,_x000D_ _x000D_ In 2016, they had a JV with Orbicular – Aleor Dermaceutical Limited and started developing dermatology products for overseas markets. In 2017, they opened another manufacturing facility for oncology medicines. In 2018, Alembic Pharmaceuticals Limited’s Aleor’s dermatology facility got approval from the Food and Drug Administration (FDA). The next year i.e., in 2019, the company made another JV to enter the Chinese market. In 2020, the company’s products in the US market made $250 million in sales._x000D_ _x000D_ As of March 2023, Alembic Pharmaceuticals Limited has 9 manufacturing plants and 2 R&D centres in India. They serve 33 states (including Union Territories) in India and 77 countries worldwide._x000D_

Business Segments of Alembic Pharmaceuticals Limited 

_x000D_ There are 3 primary business segments of the company, which are as follows:_x000D_

_x000D_
• India Formulations: Under this segment, the company develops and delivers speciality medicines that cater to various chronic and acute therapies. The therapies include dermatology, ophthalmology, dermatology, orthopaedic, cardiology, anti diabetic, anti infection, gynaecology, animal health, and more. They have an extensive product range featuring 185 brands.
_x000D_
• International Generics: Under this segment, the company manufactures products and caters to its global partners.
_x000D_
• Active Pharmaceutical Ingredients: Alembic Pharmaceuticals manufactures APIs for select formulation products under this segment.
_x000D_

_x000D_ As of March 31, 2023, the subsidiaries of Alembic Pharmaceuticals Limited are as follows:_x000D_

_x000D_
• Okner Realty LLC: This wholly-owned subsidiary of thecompany is engaged in real estate development. 
_x000D_

_x000D_

_x000D_
• Alembic Pharmaceuticals Europe Ltd: This wholly-owned subsidiary of the company was established to expand its business in Europe.
_x000D_

_x000D_

_x000D_
• Alnova Pharmaceuticals SA: This is a wholly-owned subsidiary of the company that was established to expand its business in Switzerland.
_x000D_

_x000D_

Key Personalities of Alembic Pharmaceuticals Limited

_x000D_ Pranav Amin, Managing Director _x000D_ _x000D_ Pranav Amin has been the Managing Director of Alembic Pharmaceuticals Limited since 2016. He also heads the company’s international business unit. He drives the company through empowerment, involvement and autonomy.